{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:31:02Z","timestamp":1768293062432,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The ALINE trial demonstrated the superiority of alectinib over platinum\u2010based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)\u2010positive non\u2010small\u2010cell lung cancer (NSCLC). Considering the high cost of alectinib, this study aimed to evaluate the economic value of alectinib compared to platinum\u2010based chemotherapy for treating early\u2010stage ALK\u2010positive NSCLC from the perspective of the Chinese health care system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We developed a five\u2010state Markov model with monthly cycles to estimate the lifetime costs, life\u2010years (LYs), quality\u2010adjusted life\u2010years (QALYs), and incremental cost\u2010effectiveness ratios (ICERs) in terms of cost per LY gained and per QALY gained. Costs were obtained from database, expert opinions and published literature, and utilities were primarily derived from a multicenter cross\u2010sectional study based on the Chinese population. Costs and outcomes were discounted at 5% per year. Sensitivity analyses and scenario analyses were conducted to assess uncertainty in model results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to platinum\u2010based chemotherapy, alectinib increased total costs by $16,245 and provided gains of 2.02 LYs and 1.84 QALYs over a lifetime horizon. ICERs were $8,052\/LY and $8,806\/QALY. The ICER in terms of cost per QALY gained was most sensitive to the outcome discount rate. Probabilistic sensitivity analysis indicated a 93% probability of alectinib being cost\u2010effective at a willing\u2010to pay (WTP) threshold of $12,367\/QALY (1 GDP per capita), rising to 100% at $37,100\/QALY (3 GDP per capita).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Alectinib appears to be the preferred cost\u2010effective option in the adjuvant treatment for Chinese patients with resected early\u2010stage ALK\u2010positive NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70405","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T13:13:51Z","timestamp":1731935631000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost\u2010Effectiveness Analysis of Adjuvant Alectinib versus Platinum\u2010Based Chemotherapy in Resected <scp>ALK<\/scp>\u2010Positive Non\u2010Small\u2010Cell Lung Cancer in the Chinese Health Care System"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-6381","authenticated-orcid":false,"given":"Qiran","family":"Wei","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University  Nanjing Jiangsu Province China"},{"name":"Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University  Nanjing Jiangsu Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifang","family":"Liang","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University  Nanjing Jiangsu Province China"},{"name":"Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University  Nanjing Jiangsu Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Mao","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University  Nanjing Jiangsu Province China"},{"name":"Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University  Nanjing Jiangsu Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University  Nanjing Jiangsu Province China"},{"name":"Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University  Nanjing Jiangsu Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization\u2010International Agency for Research on Cancer Cancer Today https:\/\/gco.iarc.fr\/today\/en."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0810-4"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx222"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-345"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011430"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01721-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01589"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-557"},{"key":"e_1_2_10_11_1","first-page":"484","article-title":"Adjuvant Alectinib Improves Outcomes in ALK\u2010Mutant NSCLC. Nature Reviews","volume":"21","author":"Romero D.","year":"2024","journal-title":"Clinical Oncology"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-888"},{"key":"e_1_2_10_13_1","volume-title":"Guidelines of Chinese Society of Clinical Oncoligy (CSCO) Non\u2010Small Cell Lung Cancer","author":"Chinese Society of Clinical Oncology guidelines editorial committee","year":"2023"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17012"},{"key":"e_1_2_10_17_1","volume-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Guo\u2010en L.","year":"2020"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.11.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104019"},{"key":"e_1_2_10_20_1","unstructured":"THE STATE COUNCIL The People's Republic of China \u201cNational Physical Monitoring Bulletin \u201d2023."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00437-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.461"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.07.009"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S213553"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33239"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318241f80b"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.05.005"},{"key":"e_1_2_10_28_1","unstructured":"China Population Census Yearbook \u201cOffice of the Leading Group of the State Council for the Seventh National Population Census \u201d2020."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31826b9950"},{"issue":"31","key":"e_1_2_10_30_1","first-page":"3544","article-title":"Investigation on Medical Expenses of Patients With Advanced Malignant Tumor in Registered Hospice Care Institutions in Five Provinces and Cities","volume":"13","author":"Cao H.","year":"2010","journal-title":"China General Practice"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109589"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.03.019"},{"issue":"2","key":"e_1_2_10_33_1","first-page":"5","article-title":"Comparison Analysis on Health Related Quality of Life Among Urban and Rural Residents in 4 Cities of China","volume":"34","author":"Haijing G.","year":"2015","journal-title":"Chinese Health Economics"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.942767"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107316"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0311"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2188844"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-021-00301-7"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.894656"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4798"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"e_1_2_10_42_1","unstructured":"National Institute for Health and Care Excellence \u201cDurvalumab for Maintenance Treatment of Unresectable Non\u2010Small\u2010Cell Lung Cancer After Platinum\u2010Based Chemoradiation [ID1175]: Committee Papers \u201d2019 https:\/\/www.nice.org.uk\/guidance\/ta798."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.1308"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.743558"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T05:25:26Z","timestamp":1734326726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/cam4.70405"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70405","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70405"}}